has introduced DSS, the De Simone formulation probiotic blend, in India's prescription probiotic market, valued at INR 2,071 crore. The product offers four strengths, with exclusive marketing rights for 225 billion CFU and 10 billion CFU variants. DSS, backed by extensive clinical research, is indicated for various gastrointestinal conditions. This launch aligns with Alkem's strategy to expand in chronic therapies and address growing gut health needs in India. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.